Ask about this productRelated genes to: MAPK7 antibody
- Gene:
- MAPK7 NIH gene
- Name:
- mitogen-activated protein kinase 7
- Previous symbol:
- PRKM7
- Synonyms:
- BMK1, ERK5
- Chromosome:
- 17p11.2
- Locus Type:
- gene with protein product
- Date approved:
- 1998-04-28
- Date modifiied:
- 2014-11-19
Related products to: MAPK7 antibody
Related articles to: MAPK7 antibody
- Peritoneal metastases (PMs) represent the most frequent, clinically challenging dissemination pattern in advanced gastric cancer, especially poorly cohesive (PCGC) subtype, and are associated with poor prognosis. We aimed to characterize the transcriptomic landscape of primary gastric tumors (PGTs) and matched PMs to identify differential molecular programs, tumor-microenvironment (TME) features, and potential biomarkers. - Source: PubMed
Publication date: 2026/09/02
Bencivenga MariaSimbolo MicheleGobbo StefanoFranceschi AlessandraSandri AngelaVerlato AlbertoFilippini FedericaSecchettin EricaTedone FabrizioMigliore CristinaLuchini ClaudioEwald JanLawlor Rita TeresaNottegar Alessiade Manzoni Giovanni - Glioma remains a challenging malignancy with limited therapeutic options, and the underlying molecular mechanisms driving its progression are not fully understood. Although has been implicated in various tumors, its role in glioma progression and the associated mechanisms warrant further investigation. This study aims to explore whether suppresses glioma growth and invasion by targeting , thereby regulating matrix metalloproteinases (MMPs) and epithelial-mesenchymal transition (EMT). - Source: PubMed
Publication date: 2026/06/24
Sun TingtingWang GuojinChen YeGeng XinZhu XiaofengZhou Houjun - Breast cancer is the second most common cancer worldwide and remains the leading cause of cancer-related deaths among women. Triple-negative breast cancer (TNBC) represents approximately 15-20% of all breast cancer cases and is characterized by an aggressive clinical course and a high risk of metastasis. Extracellular signal-regulated kinase 5 (ERK5) is a critical biomarker that promotes tumor progression through mechanisms involving cell proliferation, invasion, and metastasis; however, its precise role in epithelial-mesenchymal transition (EMT) in TNBC remains unclear. In this study, we analyzed data from 117 patients with TNBC and found that high ERK5 expression was significantly associated with tumor progression, shorter progression-free survival, and shorter overall survival. RNA sequencing of a highly metastatic TNBC cell line revealed that ERK5 knockdown modulated the expression of various gene clusters, particularly those associated with DNA repair, G2/M checkpoint regulation, and angiogenesis. In addition, ERK5 knockdown in a mouse xenograft model significantly suppressed tumor proliferation and lung metastasis, inhibited tumor cell migration, and reduced the expression of EMT-related proteins. Mechanistically, our data further demonstrated that ERK5 regulates the interaction between cellular JUN (c-JUN) and the vimentin promoter, thereby modulating vimentin expression and downstream signaling pathways. A significant positive correlation between ERK5 and vimentin expression in human TNBC tissue specimens further supported this regulatory association. These findings suggest that ERK5 mediates the recruitment of c-JUN to regulate vimentin expression, thereby promoting EMT and metastasis. Thus, the ERK5/c-JUN/vimentin axis may be a potential therapeutic target to improve clinical outcomes in patients with TNBC. - Source: PubMed
Publication date: 2026/06/17
Chen Chia-ChiChang Shu-JyuanLiang Cheng-LoongNguyen Hieu D HLuo Chi-WenChen Yi-ZiYang Yu-TzuHsu Mei-ChiangMoi Sin-HuaHung Chao-MingPan Mei-Ren - Regulated cell death programs influence melanoma progression and antitumor immunity, yet a robust prognostic model integrating multiple cell-death modalities remains limited. - Source: PubMed
Publication date: 2026/07/03
Wu DanZhou YuzeFang JiahongXie JiahengRen Jie - Noninvasive early detection of patients at the highest risk for the development of adverse pregnancy outcomes (APOs) such as gestational diabetes mellitus (GDM), pre-eclampsia (PE) and gestational hypertension (gHTN) remains a major challenge. Current screening approaches, including maternal blood tests and ultrasound, are limited by either cost, invasiveness, need for specialized skills, or insufficient predictive accuracy. We tested the hypothesis that a novel liquid biopsy approach using Electric Field-Induced Release and Measurement (EFIRM) platform will detect urinary transcripts/proteins in early gestation differentiating patients for the prediction of subsequently developing APOs. In a small prospective study, urine collected temporally from consented pregnant subjects who later developed GDM (n = 12), PE (n = 12), or gHTN (n = 11), were compared to subjects who never developed APOs (Controls [CON], n = 15). Isolated cell-free RNA, subjected to gold standard RNA-sequencing with differential abundances were assessed (both p-adjusted and p-values), and identified early transcriptomic signatures of these APOs. Using EFIRM-derived transcripts we validated these candidate genes and assessed corresponding protein signals. We next developed logistic regression models with leave-one-out cross-validation to preliminarily predict specific APOs. A panel of urinary transcripts (IL1A, MAPK7, TSNARE1) predicted GDM (AUC = 0.96; sensitivity = 0.95, specificity = 0.62, and NPV = 0.95), while a separate panel (NPIPB4, GSDMD, HLA-DPB1) predicted PE (area under the curve [AUC] = 0.92; sensitivity = 0.91, specificity = 0.62, and negative predictive value [NPV] = 0.90), both being distinct from gHTN. These results support the potential of EFIRM as a noninvasive, real-time, multiplexed urine liquid biopsy platform for early screening and monitoring of APOs, suggesting its future utility in prenatal care at an early gestational age. - Source: PubMed
Publication date: 2026/06/19
Ghosh ShubhamoyThamotharan ShanthieDel Vecchio GiorgiaJanzen CarlaWei FangDevaskar Sherin U